In search of a superaspirin for the heart

This publication has 10 references indexed in Scilit:

• Differential Dose-Response to Oral Xemilofiban After Antecedent Intravenous Abciximab
  Circulation, 1996
• Glycoprotein IIb/IIIa Receptor Inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG Trials into Perspective
  The American Journal of Cardiology, 1996
• A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery Stents
  New England Journal of Medicine, 1996
• Is aspirin safe in heart failure? More data
  Heart, 1996
• Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months
  The Lancet, 1994
• Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
  New England Journal of Medicine, 1994
• Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
  BMJ, 1994
• The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.
  Journal of Neurology, Neurosurgery & Psychiatry, 1991
• A Comparison of Two Doses of Aspirin (30 mg vs. 283 mg a Day) in Patients after a Transient Ischemic Attack or Minor Ischemic Stroke
  New England Journal of Medicine, 1991
• THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE
  The Lancet, 1989